Hepatic Artery Infusion Chemotherapy as a First-Line Treatment in Unresectable Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
588 patients meeting the inclusion criteria.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Meta-analysis found a pooled median overall survival of 18.3 months (95% CI: 14.1-22.4 months) and progression-free survival of 10.0 months (95% CI: 7.7-12.3 months). [CONCLUSION] HAIC demonstrates an improvement over reported survival for systemic chemotherapy alone when used as either an adjunct or in place of systemic therapy for first-line treatment in patients with cholangiocarcinoma.
[INTRODUCTION] Hepatic artery infusion chemotherapy (HAIC) has been used in efforts to improve outcomes in patients with locally advanced cholangiocarcinoma.
- 95% CI 14.1-22.4
- 연구 설계 Meta-analysis
APA
Brown N, Alexander AJ, et al. (2026). Hepatic Artery Infusion Chemotherapy as a First-Line Treatment in Unresectable Cholangiocarcinoma: A Systematic Review and Meta-Analysis.. Journal of surgical oncology, 133(4), 465-474. https://doi.org/10.1002/jso.70196
MLA
Brown N, et al.. "Hepatic Artery Infusion Chemotherapy as a First-Line Treatment in Unresectable Cholangiocarcinoma: A Systematic Review and Meta-Analysis.." Journal of surgical oncology, vol. 133, no. 4, 2026, pp. 465-474.
PMID
41588995
Abstract
[INTRODUCTION] Hepatic artery infusion chemotherapy (HAIC) has been used in efforts to improve outcomes in patients with locally advanced cholangiocarcinoma. Reported experiences are generally small institutional series. The efficacy of HAIC in locally advanced cholangiocarcinoma is not well defined.
[METHODS] We performed a comprehensive search using the electronic databases PubMed, Embase, Cochrane, ClinicalTrials. Gov, and WHO Clinical Trials from inception to August 2024.
[RESULTS] A total of 202 publications were screened, with 15 studies representing 588 patients meeting the inclusion criteria. Most patients demonstrated either a partial response or stable disease after therapy (CR: 2.5%, PR: 38.1%, SD: 43.4%, PD: 12.7%, NA: 3.3%). Meta-analysis found a pooled median overall survival of 18.3 months (95% CI: 14.1-22.4 months) and progression-free survival of 10.0 months (95% CI: 7.7-12.3 months).
[CONCLUSION] HAIC demonstrates an improvement over reported survival for systemic chemotherapy alone when used as either an adjunct or in place of systemic therapy for first-line treatment in patients with cholangiocarcinoma.
[METHODS] We performed a comprehensive search using the electronic databases PubMed, Embase, Cochrane, ClinicalTrials. Gov, and WHO Clinical Trials from inception to August 2024.
[RESULTS] A total of 202 publications were screened, with 15 studies representing 588 patients meeting the inclusion criteria. Most patients demonstrated either a partial response or stable disease after therapy (CR: 2.5%, PR: 38.1%, SD: 43.4%, PD: 12.7%, NA: 3.3%). Meta-analysis found a pooled median overall survival of 18.3 months (95% CI: 14.1-22.4 months) and progression-free survival of 10.0 months (95% CI: 7.7-12.3 months).
[CONCLUSION] HAIC demonstrates an improvement over reported survival for systemic chemotherapy alone when used as either an adjunct or in place of systemic therapy for first-line treatment in patients with cholangiocarcinoma.
MeSH Terms
Humans; Cholangiocarcinoma; Bile Duct Neoplasms; Infusions, Intra-Arterial; Hepatic Artery; Antineoplastic Combined Chemotherapy Protocols; Survival Rate